Previous Close | 23.91 |
Open | 23.43 |
Bid | 24.51 x 200 |
Ask | 24.54 x 200 |
Day's Range | 23.02 - 24.61 |
52 Week Range | 20.67 - 39.83 |
Volume | |
Avg. Volume | 1,051,569 |
Market Cap | 3.044B |
Beta (5Y Monthly) | 0.94 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.23 |
Earnings Date | Aug 05, 2024 - Aug 09, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 52.43 |
PASADENA, Calif., June 03, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducing t
PASADENA, Calif., May 31, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
PASADENA, Calif., May 29, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with robust and durable reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation today at the Euro